{"filing":{"accession_number":"0001140361-26-026933","cik":"0001708688","ticker":"IFRX","company_name":"InflaRx N.V.","form":"6-K","filing_date":"2026-06-30","report_date":null,"primary_document":"ef20077063_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1708688/000114036126026933/ef20077063_6k.htm"},"events":[{"id":15008,"run_id":13389,"accession_number":"0001140361-26-026933","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"InflaRx announced it is assessing a broadened development strategy for ANCA-associated vasculitis (AAV) in Europe following the EMA's recommendation to revoke marketing authorization for Tavneos (a competitor product). The company intends to engage with the EMA regarding regulatory pathways for both vilobelimab and izicopan in AAV, representing a material strategic pivot in response to evolving market conditions. This is a significant operational and strategic business development that would affect investor assessment of the company's pipeline and competitive positioning, though it does not fit neatly into discrete event categories like M\u0026A, exec changes, or financial results.","company_name":"InflaRx N.V.","ticker":"IFRX","filing_date":"2026-06-30","form":"6-K","submitted_at":null,"items":[{"id":12614,"accession_number":"0001140361-26-026933","item_number":"EX-99.1","item_title":"ef20077063_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"InflaRx announced it is assessing a broadened development strategy for ANCA-associated vasculitis (AAV) in Europe following the EMA's recommendation to revoke marketing authorization for Tavneos (a competitor product). The company intends to engage with the EMA regarding regulatory pathways for both vilobelimab and izicopan in AAV, representing a material strategic pivot in response to evolving market conditions. This is a significant operational and strategic business development that would affect investor assessment of the company's pipeline and competitive positioning, though it does not fit neatly into discrete event categories like M\u0026A, exec changes, or financial results.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:18:52.032943+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12614,"accession_number":"0001140361-26-026933","item_number":"EX-99.1","item_title":"ef20077063_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"InflaRx announced it is assessing a broadened development strategy for ANCA-associated vasculitis (AAV) in Europe following the EMA's recommendation to revoke marketing authorization for Tavneos (a competitor product). The company intends to engage with the EMA regarding regulatory pathways for both vilobelimab and izicopan in AAV, representing a material strategic pivot in response to evolving market conditions. This is a significant operational and strategic business development that would affect investor assessment of the company's pipeline and competitive positioning, though it does not fit neatly into discrete event categories like M\u0026A, exec changes, or financial results.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:18:52.032943+00:00","company_name":"InflaRx N.V.","ticker":"IFRX","filing_date":"2026-06-30"}]}